NDT Pharmaceuticals Inc. (NDTP)
USD 0.07
(-58.27%)
USD 0.07
(-58.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 41.79 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 358.97 Thousand USD | 0.34% |
| 2016 | 357.77 Thousand USD | 0.34% |
| 2015 | 356.57 Thousand USD | 0.34% |
| 2014 | 355.37 Thousand USD | 0.0% |
| 2010 | 400.7 Thousand USD | 0.0% |
| 2007 | 124.64 Thousand USD | 1166.11% |
| 2006 | 9845.00 USD | 72.72% |
| 2005 | 5700.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 53.48 Thousand USD | 23.47% |
| 2024 Q1 | 43.31 Thousand USD | 3.64% |
| 2023 Q3 | 39.07 Thousand USD | 5.56% |
| 2023 Q4 | 41.79 Thousand USD | 6.97% |
| 2023 FY | 41.79 Thousand USD | 0.0% |
| 2023 Q1 | 27.89 Thousand USD | 0.0% |
| 2023 Q2 | 37.02 Thousand USD | 32.72% |
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 358.97 Thousand USD | 0.34% |
| 2016 FY | 357.77 Thousand USD | 0.34% |
| 2015 FY | 356.57 Thousand USD | 0.34% |
| 2014 FY | 355.37 Thousand USD | 0.0% |
| 2011 Q1 | 405.86 Thousand USD | 1.29% |
| 2011 Q2 | 401.82 Thousand USD | -1.0% |
| 2010 Q1 | 388.74 Thousand USD | 0.0% |
| 2010 FY | 400.7 Thousand USD | 0.0% |
| 2010 Q4 | 400.7 Thousand USD | 2.25% |
| 2010 Q3 | 391.9 Thousand USD | -0.93% |
| 2010 Q2 | 395.6 Thousand USD | 1.76% |
| 2008 Q2 | 176 Thousand USD | 2.18% |
| 2008 Q1 | 172.25 Thousand USD | 38.19% |
| 2007 Q4 | 124.64 Thousand USD | 503.39% |
| 2007 Q3 | 20.65 Thousand USD | 120.19% |
| 2007 Q2 | 9382.00 USD | -32.84% |
| 2007 Q1 | 13.96 Thousand USD | 41.89% |
| 2007 FY | 124.64 Thousand USD | 1166.11% |
| 2006 Q2 | 10.14 Thousand USD | -14.63% |
| 2006 Q3 | 11.23 Thousand USD | 10.84% |
| 2006 Q4 | 9845.00 USD | -12.4% |
| 2006 FY | 9845.00 USD | 72.72% |
| 2006 Q1 | 11.87 Thousand USD | 0.0% |
| 2005 FY | 5700.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -52.368% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.558% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.942% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 94.832% |
| Rebus Holdings, Inc. | 5.24 Million USD | 99.203% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.929% |
| Qrons Inc. | 1.48 Million USD | 97.192% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 96.591% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.944% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 6.482% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.703% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.922% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.564% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 90.085% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.916% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.652% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 98.915% |
| Mesoblast Limited | 188.44 Million USD | 99.978% |
| Marizyme, Inc. | 26.67 Million USD | 99.843% |
| Genus plc | 485 Million USD | 99.991% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 99.285% |
| Pharming Group N.V. | 244.07 Million USD | 99.983% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 97.921% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 98.339% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 98.9% |
| ContraFect Corporation | 32.53 Million USD | 99.872% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 97.89% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 98.908% |
| IMV Inc. | 37.93 Million USD | 99.89% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.645% |
| MultiCell Technologies, Inc. | 1617.67 USD | -2483.902% |
| ONE Bio Corp. | 27.49 Million USD | 99.848% |
| Accustem Sciences Inc. | 1.07 Million USD | 96.127% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.946% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 98.024% |
| Q BioMed Inc. | 8.13 Million USD | 99.486% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.95% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 99.188% |
| Biomind Labs Inc. | 1.49 Million USD | 97.211% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.965% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.538% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.773% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 97.085% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 70.584% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 79.216% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 99.273% |
| GB Sciences, Inc. | 5.41 Million USD | 99.228% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.417% |
| HST Global, Inc. | 593.59 Thousand USD | 92.958% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 96.68% |
| Halberd Corporation | 728.71 Thousand USD | 94.264% |
| Enzolytics Inc. | 365.26 Million USD | 99.989% |
| Agentix Corp. | 2.51 Million USD | 98.335% |
| Resverlogix Corp. | 67.39 Million USD | 99.938% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 95.016% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.991% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 97.561% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.831% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.649% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 98.86% |
| AVAX Technologies, Inc. | 3.99 Million USD | 98.953% |
| Zenith Capital Corp. | 27.56 Thousand USD | -51.616% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 82.486% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 98.881% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 93.861% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 98.459% |
| Kadimastem Ltd | 3.5 Million USD | 98.807% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 37.547% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.917% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.737% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 91.005% |
| LadRx Corporation | 2.2 Million USD | 98.101% |
| Cell Source, Inc. | 15.8 Million USD | 99.736% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.234% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.234% |
| NovAccess Global Inc. | 7.86 Million USD | 99.468% |
| Affymax, Inc. | 8.87 Million USD | 99.529% |
| Itoco Inc. | 1.65 Million USD | 97.472% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 97.963% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 99.309% |
| Mobile Lads Corp. | 1.31 Million USD | 96.818% |
| CytoDyn Inc. | 127.89 Million USD | 99.967% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 97.331% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.622% |
| SYBLEU INC | 681.41 Thousand USD | 93.866% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 99.315% |
| International Stem Cell Corporation | 5.27 Million USD | 99.208% |
| Bioxytran, Inc. | 3.24 Million USD | 98.714% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 93.321% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 99.095% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.898% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.812% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 97.936% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 99.237% |
| Neutra Corp. | 973.52 Thousand USD | 95.706% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.856% |
| PureTech Health plc | 125.58 Million USD | 99.967% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 98.887% |
| IXICO plc | 1.9 Million USD | 97.8% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.796% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.96% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.983% |